<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24626659</article-id>
      <article-id pub-id-type="pmc">3938365</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20142785</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fabry disease: clinical and genotypic aspects of three cases in first
degree relatives<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Let&#xED;cia Bueno Nunes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Badiz</surname>
            <given-names>Thais Cardoso de Mello Tucunduva</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Enokihara</surname>
            <given-names>Milvia Maria Sim&#xF5;es e Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porro</surname>
            <given-names>Adriana Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, Dermatologist - Graduate course in clinical dermatology,
Dermatology Department, Escola Paulista de Medicina - Universidade Federal de S&#xE3;o Paulo
(EPM-UNIFESP) - S&#xE3;o Paulo (SP), Brazil. </aff>
      <aff id="aff02"><label>2</label> MD, Dermatologist - Graduate course in Dermatoscopy, Dermatology
Department, Escola Paulista de Medicina - Universidade Federal de S&#xE3;o Paulo
(EPM-UNIFESP) - S&#xE3;o Paulo (SP), Brazil. </aff>
      <aff id="aff03"><label>3</label> MD, PhD - Dermatopathologist at the Dermatology and Pathology
departments, Escola Paulista de Medicina - Universidade Federal de S&#xE3;o Paulo
(EPM-UNIFESP) - S&#xE3;o Paulo (SP), Brazil. </aff>
      <aff id="aff04"><label>4</label> MD, PhD - Adjunct Professor of the Dermatology Department, Escola
Paulista de Medicina - Universidade Federal de S&#xE3;o Paulo (EPM-UNIFESP) - S&#xE3;o Paulo (SP),
Brazil. </aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Let&#xED;cia Bueno Nunes da Silva, Rua Borges Lagoa, 508,
Vila Clementino, 04038-001 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>leticiabns@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>1</issue>
      <fpage>141</fpage>
      <lpage>143</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xAE;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>Fabry disease is an X-linked, lysosomal storage disease caused by the inherited
deficiency of the enzyme <bold>&#x3B1;</bold>-galactosidase A. The diagnosis is usually
late, with renal, cardiovascular and/or cerebral complications that reduce life
expectancy. Angiokeratomas are asymptomatic lesions present as the initial
manifestation and usually less appreciated. Their detection is important for early
diagnosis and institution of treatment with enzyme replacement therapy, which
prevents late complications reducing morbidity and mortality. We report a case of a
male teenager with acroparestesias and angiokeratomas. Family medical research
discovered that his mother and brother had similar signs and symptoms and that the
three patients had the same mutation in the gene encoding the enzyme, confirming the
diagnosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Angiokeratoma</kwd>
        <kwd>Fabry disease</kwd>
        <kwd>alpha-Galactosidase</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Fabry disease is a rare storage metabolic disease, linked to X chromosome, caused by
deficiency of &#x3B1;- galactosidase A (&#x3B1;-Gal A) lysosomal hydrolase activity, leading to the
accumulation of two neutral glycosphingolipids, globotriaosylceramide (GL-3 or Gb3) and
digalactosylceramide, in several tissues, with progressive multisystemic
damage.<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r05" ref-type="bibr">5</xref></sup>
</p>
      <p>The angiokeratomas are part of the initial clinical presentation, although asymptomatic.
Angiokeratomas, acroparestesias and non-specific systemic symptoms are not initially
associated with Fabry disease, which postpones the beginning of enzyme replacement
therapy (ERT), increasing the risk of late complications.<sup><xref rid="r06" ref-type="bibr">6</xref></sup>
</p>
      <p>We report three cases of Fabry disease in two male brothers, in its classical form, as
well as in the oligosymptomatic mother.</p>
    </sec>
    <sec>
      <title>CASES REPORT</title>
      <p>
<bold>Case 1:</bold> 16-year-old male, with asymptomatic periumbilical lesions since his
first years of life, progressing in number and size for the last 3 years. He presented
right hypoacusia, tingling in hands and feet and burning plantar pain, which worsened
with hot weather and physical activity.</p>
      <p>At the dermatological exam he presented erythematous-violaceous papules of keratotic
surface, grouped on the upper limbs, paravertebral, paraumbilical, inguinal, scrotum and
penile regions, right thigh and knees (<xref ref-type="fig" rid="f01">Figure 1</xref>).
In the ophthalmological investigation the diagnosis was cornea verticillata (<xref ref-type="fig" rid="f02">Figure 2</xref>). He presented hearing deficit in the right
ear at audiometry. In complementary exams, he showed high 24hours proteinuria (0.14; VR
&lt; 0.05); remaining exams were normal (blood count, renal function, microalbuminuria,
ECG, spirometry and cranial magnetic resonance imaging-MRI). The deficiency of &#x3B1;-Gal
activity was confirmed in the plasma (0.0 umol/h of protein; &gt; 2.5) and leukocytes
through paper filter (0.16 nmol / h / mg of protein; &gt; 1.4). The biopy of umbilical
lesion resulted compatible with angiokeratoma (<xref ref-type="fig" rid="f03">Figure
3</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>
<bold>A.</bold> Keratotic erythematous-violaceous papules, distributed on the
umbilical and paraumbilical areas. <bold>B.</bold> Keratotic violaceous papules
distributed on scrotum and penile body</p>
        </caption>
        <graphic xlink:href="abd-89-01-0141-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Cornea verticillata: Yellowish lines that converge to a spot close to central
cornea region</p>
        </caption>
        <graphic xlink:href="abd-89-01-0141-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>
<bold>A.</bold> Proliferation of capillary vases, ectasia and congestion of the
lumen in the papillary dermis, thickening of epidermis (HE100X). <bold>B.</bold>
Proliferation of capillary vases, ectasied, congested close to the dome of the
papillary dermis (HE 400X)</p>
        </caption>
        <graphic xlink:href="abd-89-01-0141-g03"/>
      </fig>
      <p>
<bold>Case 2</bold>: an 11-year-old boy presented burning pains in the lower limbs,
which worsened with hot weather, although less intensively than in his brother's case
(Case 1). During examination angiokeratomas were noticed, limited to the periumbilical
region. He presented cornea verticillata, while the audiometry and other laboratory,
electrocardiographic and imaging exams were normal. Enzyme &#x3B1;- Gal A deficiency was
observed in the plasma and leukocytes (plasma: 0.11 umol/h; leukocytes: 0.46
nmol/mg/h).</p>
      <p>
<bold>Case 3</bold>: a 39-year-old female, mother of patients 1 and 2, presented with
mild acroparestesia and cornea verticillata, without skin lesions. Audiometry revealed
diminished hearing in the right ear and slight loss in the left, discrete proteinuria
(0.09) and microalbuminuria (20.93 VR &lt; 20 ). Normal blood count, renal function,
ESR, ECG and cranial MRI. Dosage of &#x3B1;-Gal A activity in the plasma was within normal
range (3.02 umol/h).</p>
      <p>Genotyping of the 3 patients revealed a similar mutation: Exon 7 Arg 342 Gln. In the
two-year followup, patient 1 presented worsening of lower limb pains and microangiopathy
was detected in cranial MRI. Patient 2 started presenting proteinuria and increase of
angiokeratomas in size, number and distribution. The mother remained stable. The three
patients still have not started enzyme replacement due to family decision of postponing
the beginning of treatment.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Fabry disease was originally described in 1898 as '<italic>angiokeratoma corporis
diffusum</italic>' by Anderson and Fabry.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> Later it was recognized
as a systemic lysosomal storage disease, caused by a mutation of &#x3B1;-Gal gene A(Xq22.1),
leading to alteration of enzyme expression.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> This deficiency leads to
accumulation of neutral glycosphingolipids, particularly globotriaosylceramide (Gb3) and
digalactosylceramide, mainly in the central nervous system, skin, heart, kidneys,
auditory system and eyes.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>
</p>
      <p>The clinical expression of the disease depends on the &#x3B1;-galactosidase enzyme activity,
whereas patients with residual enzymatic activity show a milder clinical picture, with
predominance of cardiac alterations, possibly with minimal renal damage and absence of
acroparestesia, which does not occur in the classical form of the disease, when the
enzymatic activity is absent.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> This can be explained by more than 400
different gene mutations, some of them leading to some residual enzymatic activity
varying between 2 to 25%.<sup><xref rid="r02" ref-type="bibr">2</xref></sup>
</p>
      <p>Even though it is considered a recessive disease linked to X chromosome, heterozygous
women can manifest the disease symptoms in 70 % of the cases, due to random activation
of chromosome X, not being merely carriers of the mutation.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> This way, it is
necessary to investigate and follow up female patients of families that carry Fabry
disease, as was done with the patients' mother.</p>
      <p>The classical form occurs in the male gender, as presented in the two brothers. The
initial symptoms appeared in infancy, predominantly neurological, like acroparestesias,
generalized pains, change of thermal sensitivity, hearing loss and hypohidrosis, but
also gastrointestinal, including abdominal pain and change of intestinal
habit.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup> The cornea verticillata may be present since early
childhood.<sup><xref rid="r06" ref-type="bibr">6</xref></sup> Angiokeratomas are
papules of red to purplish coloration, of varying sizes and tending to grow in number
and size with age. They are distributed mainly on the periumbilical and inguinal areas,
in swimsuit form.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> Angiokeratomas and cornea verticillata, when present, are
a clue to an early diagnosis.<sup><xref rid="r07" ref-type="bibr">7</xref></sup>
</p>
      <p>The late manifestations occur in the third and fourth decades; the main ones are:
chronic renal disease, cardiac arrhythmias and cerebral vascular accident, which
contribute to reduce life expectancy of patients by 15 to 20 years.<sup><xref rid="r07" ref-type="bibr">7</xref></sup> Early diagnosis is important for the
establishment of enzymatic replacement treatment, diminishing Gb3 deposits in the
vascular endothelium and plasma, with stabilization of renal function in children and
postponing disease progress in adults.<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> Recent studies suggest that, in spite of variable ERT response
among patient subgroups, the treatment started before the occurrence of irreversible
damage to organs could prevent late complications, with reduction of morbidity and
mortality related to the disease.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup>
</p>
      <p>We reported three cases of Fabry disease in first-degree relatives. The index patient
received the diagnosis at 16 years of age, despite the presence of angiokeratomas since
early childhood, which demonstrates the importance of dermatologists and pediatricians
knowing the condition to ensure that early enzymatic treatment is ministered, capable of
avoiding late complications of the disease.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work performed at the Dermatology department, Escola Paulista de Medicina -
Universidade Federal de S&#xE3;o Paulo (EPM-UNIFESP) - S&#xE3;o Paulo (SP), Brazil.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial Support: none</p>
      </fn>
      <fn fn-type="conflict">
        <p>Conflict of Interests: none</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boggio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Luna</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Abad</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Larralde</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fabry Disease</article-title>
          <source>An Bras Dermatol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>367</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="pmid">19851669</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiffmann</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Fabry disease</article-title>
          <source>Pharmacol Ther</source>
          <year>2009</year>
          <volume>122</volume>
          <fpage>65</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">19318041</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>D'Almeida</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kyosen</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Takata</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Delgado</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>AM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Guidelines to diagnosis and monitoring of Fabry Disease and review of
treatment experiences</article-title>
          <source>J Pediatr</source>
          <year>2009</year>
          <volume>155</volume>
          <fpage>S19</fpage>
          <lpage>S31</lpage>
          <pub-id pub-id-type="pmid">19765408</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Narrative review: Fabry disease</article-title>
          <source>Ann Intern Med</source>
          <year>2007</year>
          <volume>146</volume>
          <fpage>425</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="pmid">17371887</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramaswami</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Update on role of agalsidase alfa in management of Fabry
disease</article-title>
          <source>Drug Des Devel Ther</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>155</fpage>
          <lpage>173</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramaswami</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Whybra</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pintos-Morell</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sunder-Plassmann</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Clinical manifestations of Fabry disease in children: Data from the
Fabry Outcome Survey</article-title>
          <source>Acta Paediatr</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>86</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">16498740</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zarate</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Hopkin</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Fabry's disease</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>372</volume>
          <fpage>1427</fpage>
          <lpage>1435</lpage>
          <pub-id pub-id-type="pmid">18940466</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiffmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Reimschisel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Castaneda</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lien</surname>
              <given-names>YH</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Four-year prospective clinical trial of agalsidase alfa in children
with Fabry disease</article-title>
          <source>J Pediatr</source>
          <year>2010</year>
          <volume>156</volume>
          <fpage>832</fpage>
          <lpage>837</lpage>
          <page-range>832-7,837.e1</page-range>
          <pub-id pub-id-type="pmid">20097359</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banikazemi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bultas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Waldek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wilcox</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Whitley</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Agalsidase-beta therapy for advanced Fabry disease: a randomized
trial</article-title>
          <source>Ann Intern Med</source>
          <year>2007</year>
          <volume>146</volume>
          <fpage>77</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">17179052</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alegra</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vairo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Souza</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Krug</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>IV</given-names>
            </name>
          </person-group>
          <article-title>Enzyme replacement therapy for Fabry disease: A systematic review and
meta-analysis</article-title>
          <source>Genet Mol Biol</source>
          <year>2012</year>
          <volume>35</volume>
          <fpage>947</fpage>
          <lpage>954</lpage>
          <pub-id pub-id-type="pmid">23413206</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
